The mechanism of action of BCG therapy for bladder cancer—a current perspective

[1]  M. Glickman,et al.  Oncogenic activation of Pak1-dependent pathway of macropinocytosis determines BCG entry into bladder cancer cells. , 2013, Cancer research.

[2]  H. G. van der Poel,et al.  ICUD-EAU International Consultation on Bladder Cancer 2012: Urothelial carcinoma of the prostate. , 2013, European urology.

[3]  Zhi-ren Zhang,et al.  Macrophages in Tumor Microenvironments and the Progression of Tumors , 2012, Clinical & developmental immunology.

[4]  M. Albert,et al.  Preexisting BCG-Specific T Cells Improve Intravesical Immunotherapy for Bladder Cancer , 2012, Science Translational Medicine.

[5]  Yi Luo,et al.  Anti-interleukin-10R1 monoclonal antibody enhances bacillus Calmette-Guérin induced T-helper type 1 immune responses and antitumor immunity in a mouse orthotopic model of bladder cancer. , 2012, The Journal of urology.

[6]  M. Glickman,et al.  Inhibition of Mycobacterial Infection by the Tumor Suppressor PTEN* , 2012, The Journal of Biological Chemistry.

[7]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[8]  E. Zwarthoff,et al.  Markers predicting response to bacillus Calmette-Guérin immunotherapy in high-risk bladder cancer patients: a systematic review. , 2012, European urology.

[9]  S. K. Watkins,et al.  Immune suppression in the tumor microenvironment: a role for dendritic cell-mediated tolerization of T cells , 2012, Cancer Immunology, Immunotherapy.

[10]  M. Babjuk,et al.  EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. , 2011, European urology.

[11]  Kehu Yang,et al.  Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer. , 2011, The Cochrane database of systematic reviews.

[12]  A. Bergeron,et al.  Toll-like receptors in normal and malignant human bladders. , 2011, The Journal of urology.

[13]  M. Oosting,et al.  Innate Immune Recognition of Mycobacterium tuberculosis , 2011, Clinical & developmental immunology.

[14]  D. Lamm,et al.  Bacillus Calmette-Guérin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer. , 2010, The Journal of urology.

[15]  Yi Luo,et al.  Interleukin‐10 inhibits Mycobacterium bovis bacillus Calmette–Guérin (BCG)‐induced macrophage cytotoxicity against bladder cancer cells , 2010, Clinical and experimental immunology.

[16]  H. Trindade,et al.  Efficacy of bacille Calmette-Guérin immunotherapy predicted by expression of antigen-presenting molecules and chemokines. , 2009, Urology.

[17]  G. Bahar,et al.  Predictive value of urinary interleukin-8 cutoff point for recurrences after transurethral resection plus induction bacillus Calmette-Guérin treatment in non-muscle-invasive bladder tumors. , 2009, Clinical genitourinary cancer.

[18]  L. Lacombe,et al.  Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy. , 2009, European urology.

[19]  W. See,et al.  Bacille‐Calmette Guèrin induces caspase‐independent cell death in urothelial carcinoma cells together with release of the necrosis‐associated chemokine high molecular group box protein 1 , 2009, BJU international.

[20]  K. Aozasa,et al.  Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation. , 2009, The Journal of urology.

[21]  Yi Luo,et al.  Recombinant bacillus Calmette-Guérin (BCG) expressing interferon-alpha 2B enhances human mononuclear cell cytotoxicity against bladder cancer cell lines in vitro , 2009, Cancer Immunology, Immunotherapy.

[22]  E. Shinya,et al.  A possible mechanism of intravesical BCG therapy for human bladder carcinoma: involvement of innate effector cells for the inhibition of tumor growth , 2009, Cancer Immunology, Immunotherapy.

[23]  M. Babjuk,et al.  EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. , 2008, European urology.

[24]  A. Goel,et al.  The effect of intravesical instillation of antifibrinolytic agents on bacillus Calmette-Guerin treatment of superficial bladder cancer: A pilot study , 2008, Indian journal of urology : IJU : journal of the Urological Society of India.

[25]  Eun-Kyeong Jo,et al.  Mycobacterial interaction with innate receptors: TLRs, C-type lectins, and NLRs , 2008, Current opinion in infectious diseases.

[26]  P. Schellhammer,et al.  Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. , 2007, The Journal of urology.

[27]  A. Eiján,et al.  Cathepsin B is involved in the apoptosis intrinsic pathway induced by Bacillus Calmette-Guérin in transitional cancer cell lines. , 2007, International journal of molecular medicine.

[28]  R. Mahendran,et al.  Internalization of Mycobacterium bovis, Bacillus Calmette Guerin, by bladder cancer cells is cytotoxic. , 2007, Oncology reports.

[29]  M. Naoe,et al.  Bacillus Calmette‐Guérin‐pulsed dendritic cells stimulate natural killer T cells and γδT cells , 2007 .

[30]  G. Zabucchi,et al.  The role of granulocytes following intravesical BCG prophylaxis. , 2007, European urology.

[31]  K. Sugimura,et al.  Significance of target cell infection and natural killer cells in the anti-tumor effects of bacillus Calmette-Guerin in murine bladder cancer. , 2007, Oncology reports.

[32]  P. Sharma,et al.  Immunotherapeutic strategies for high-risk bladder cancer. , 2007, Seminars in oncology.

[33]  Y. Uekado,et al.  Intravesical instillation therapy with bacillus Calmette‐Guérin for superficial bladder cancer: Study of the mechanism of bacillus Calmette‐Guérin immunotherapy , 2007, International journal of urology : official journal of the Japanese Urological Association.

[34]  Y. Luo,et al.  Mycobacterium bovis bacillus Calmette–Guérin (BCG) induces human CC‐ and CXC‐chemokines in vitro and in vivo , 2006, Clinical and experimental immunology.

[35]  G. Dhom,et al.  Urothelial carcinoma of the prostate , 1986, Journal of Cancer Research and Clinical Oncology.

[36]  M. Naoe,et al.  Bacillus Calmette-Guérin-pulsed dendritic cells stimulate natural killer T cells and gammadeltaT cells. , 2007, International journal of urology : official journal of the Japanese Urological Association.

[37]  T. Griffith,et al.  Identification of the Mycobacterial Subcomponents Involved in the Release of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand from Human Neutrophils , 2006, Infection and Immunity.

[38]  D. Evanoff,et al.  Role of Th1‐stimulating cytokines in bacillus Calmette–Guérin (BCG)‐induced macrophage cytotoxicity against mouse bladder cancer MBT‐2 cells , 2006, Clinical and experimental immunology.

[39]  M. Stöckle,et al.  Neutrophil granulocytes are required for effective Bacillus Calmette-Guérin immunotherapy of bladder cancer and orchestrate local immune responses. , 2006, Cancer research.

[40]  Ruifa Han,et al.  Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. , 2006, Urology.

[41]  C. Porter,et al.  Treatment of upper tract urothelial carcinoma: a review of surgical and adjuvant therapy. , 2006, Reviews in urology.

[42]  T. Griffith,et al.  Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guerin (BCG) results in the release of functional soluble TRAIL/Apo-2L. , 2005, Blood.

[43]  S. Naito,et al.  Importance of Urinary Interleukin-18 in Intravesical Immunotherapy with Bacillus Calmette-Guérin for Superficial Bladder Tumors , 2005, Urologia Internationalis.

[44]  W. See,et al.  BCG directly induces cell cycle arrest in human transitional carcinoma cell lines as a consequence of integrin cross-linking , 2005, BMC urology.

[45]  L. Gomella,et al.  Induction of TH1- and TH2-associated cytokine mRNA in mouse bladder following intravesical growth of the murine bladder tumor MB49 and BCG immunotherapy , 1994, Cancer Immunology, Immunotherapy.

[46]  J. Witjes,et al.  Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin , 2005, Cancer Immunology, Immunotherapy.

[47]  F. Debruyne,et al.  Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer , 2005, Cancer Immunology, Immunotherapy.

[48]  C. Ogden,et al.  Urine dendritic cells: a noninvasive probe for immune activity in bladder cancer? , 2004, BJU international.

[49]  T. Ratliff.  Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand: A Novel Mechanism for Bacillus Calmette-Guerin-Induced Antitumor Activity , 2004 .

[50]  M. Jacobsen,et al.  Mechanisms of bacillus Calmette-Guerin mediated natural killer cell activation. , 2004, The Journal of urology.

[51]  K. Kurth,et al.  Role of urothelial cells in BCG immunotherapy for superficial bladder cancer , 2004, British Journal of Cancer.

[52]  D. Evanoff,et al.  Recombinant Mycobacterium bovis bacillus Calmette‐Guérin (BCG) expressing mouse IL‐18 augments Th1 immunity and macrophage cytotoxicity , 2004, Clinical and experimental immunology.

[53]  T. Wilt,et al.  Intravesical bacillus Calmette‐Guérin is superior to mitomycin C in reducing tumour recurrence in high‐risk superficial bladder cancer: a meta‐analysis of randomized trials , 2004, BJU international.

[54]  M. O'Donnell,et al.  Immunotherapy of Experimental Bladder Cancer with Recombinant BCG Expressing Interferon-&ggr; , 2004, Journal of immunotherapy.

[55]  T. Reijke,et al.  Role of interleukin-8 in onset of the immune response in intravesical BCG therapy for superficial bladder cancer , 2004, Urological Research.

[56]  E. Vollmer,et al.  Specific binding of bacillus Calmette-Guérin to urothelial tumor cells in vitro , 2004, World Journal of Urology.

[57]  T. Reijke,et al.  Cytokine production by the human bladder carcinoma cell line T24 in the presence of bacillus Calmette-Guerin (BCG) , 2004, Urological Research.

[58]  Wafik S El-Deiry,et al.  TRAIL and apoptosis induction by TNF-family death receptors , 2003, Oncogene.

[59]  K. Naito,et al.  Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Guérin immunotherapy for carcinoma in situ of the bladder , 2003, Cancer Immunology, Immunotherapy.

[60]  Yi Luo,et al.  Role of Th1 and Th2 cytokines in BCG-induced IFN-gamma production: cytokine promotion and simulation of BCG effect. , 2003, Cytokine.

[61]  Anant Kumar,et al.  Urinary interleukin-8 predicts the response of standard and low dose intravesical bacillus Calmette-Guerin (modified Danish 1331 strain) for superficial bladder cancer. , 2002, The Journal of urology.

[62]  D. Lamm,et al.  Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. , 2002, The Journal of urology.

[63]  H. Akaza,et al.  Surface antigen expression on bladder tumor cells induced by bacillus Calmette‐Guérin (BCG): A role of BCG internalization into tumor cells , 2002, International journal of urology : official journal of the Japanese Urological Association.

[64]  A. Böhle,et al.  IFN‐gamma and IL‐12 but not IL‐10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer , 2002, Clinical and experimental immunology.

[65]  J. Patard,et al.  Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer. , 2002, Journal of Urology.

[66]  T. Wilt,et al.  A systematic review of intravesical bacillus Calmette‐Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer , 2001, BJU international.

[67]  T. Ratliff,et al.  NK cells are essential for effective BCG immunotherapy , 2001, International journal of cancer.

[68]  A. Böhle,et al.  Activation of Natural Killer Cells by Bacillus Calmette–Guérin , 2001, European Urology.

[69]  U. Studer,et al.  Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin. , 2000, The Journal of urology.

[70]  Osamu Takeuchi,et al.  Maturation of Human Dendritic Cells by Cell Wall Skeleton of Mycobacterium bovis Bacillus Calmette-Guérin: Involvement of Toll-Like Receptors , 2000, Infection and Immunity.

[71]  H. Flad,et al.  Perforin-mediated lysis of tumor cells by Mycobacterium bovis Bacillus Calmette-Guérin-activated killer cells. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[72]  S. Matsumoto,et al.  Murine IL-2 secreting recombinant Bacillus Calmette-Guerin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2. , 2000, The Journal of urology.

[73]  H. Dockrell,et al.  Monocyte-derived macrophage cytokine responses induced by M. bovis BCG. , 2000, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[74]  W. See,et al.  AUTOCRINE IL-6 PRODUCTION BY HUMAN TRANSITIONAL CARCINOMA CELLS UPREGULATES EXPRESSION OF THE α5β1 FIBRONECTIN RECEPTOR , 2000 .

[75]  W. See,et al.  Autocrine IL-6 production by human transitional carcinoma cells upregulates expression of the alpha5beta1 firbonectin receptor. , 2000, The Journal of urology.

[76]  S. Matsumoto,et al.  Enhancing Effect of an Inhibitor of Nitric Oxide Synthesis on Bacillus Calmette‐Guérin‐induced Macrophage Cytotoxicity against Murine Bladder Cancer Cell Line MBT‐2 in vitro , 2000, Japanese journal of cancer research : Gann.

[77]  T. Ratliff,et al.  Role of a bacillus calmette‐guérin fibronectin attachment protein in BCG‐induced antitumor activity , 2000, International journal of cancer.

[78]  C. Baird,et al.  The pilot study. , 2000, Orthopedic nursing.

[79]  山田 博.  Murine IL-2 Secreting Recombinant Bacillus Calmette-guerin Augments Macrophage-Mediated Cytotoxicity against Murine Bladder Cancer MBT-2 , 2000 .

[80]  K. Kurth,et al.  BCG internationalization in human bladder cancer cell lines, especially with regard to cell surface-expressed fibronectin , 2000 .

[81]  Y. Luo,et al.  Role of IL-12 in the induction and potentiation of IFN-gamma in response to bacillus Calmette-Guérin. , 1999, Journal of immunology.

[82]  H. Flad,et al.  Bacillus-Calmette-Guérin (BCG) and 3D tumors: an in vitro model for the study of adhesion and invasion. , 1999, The Journal of urology.

[83]  J. Wang,et al.  Macrophages are a significant source of type 1 cytokines during mycobacterial infection. , 1999, The Journal of clinical investigation.

[84]  H. Khoo,et al.  Effects of bacillus Calmette-Guèrin and interferon alpha-2B on cytokine production in human bladder cancer cell lines. , 1999, The Journal of urology.

[85]  Kanetake,et al.  Systemic immune response after intravesical instillation of bacille Calmette–Guérin (BCG) for superficial bladder cancer , 1999, Clinical and experimental immunology.

[86]  K. Kurth,et al.  BCG-induced interleukin-6 upregulation and BCG internalization in well and poorly differentiated human bladder cancer cell lines. , 1998, European cytokine network.

[87]  J. Ernst,et al.  Macrophage Receptors for Mycobacterium tuberculosis , 1998, Infection and Immunity.

[88]  N. Takahashi,et al.  Are BCG effects against urinary bladder carcinoma cell line T24 correlated with apoptosis in vitro? , 1997, Urologia internationalis.

[89]  A. Jackson,et al.  Production of IL-5, a classical T(H)2 cytokine, following bacillus Calmette guerin immunotherapy of bladder cancer. , 1996, International journal of oncology.

[90]  R. Kaempfer,et al.  Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[91]  T. D. de Reijke,et al.  Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value. , 1996, The Journal of urology.

[92]  S. Prescott,et al.  Interleukin-6 production by bladder tumors is upregulated by BCG immunotherapy. , 1995, The Journal of urology.

[93]  R. Penny,et al.  Bacillus Calmette-Guerin (BCG) enhances monocyte- and lymphocyte-mediated bladder tumour cell killing. , 1995, British Journal of Cancer.

[94]  S. Prescott,et al.  Changes in urinary cytokines and soluble intercellular adhesion molecule‐1 (ICAM‐1) in bladder cancer patients after Bacillus Calmette—Guérin (BCG) immunotherapy , 1995, Clinical and experimental immunology.

[95]  S. Prescott,et al.  Bacillus-calmette-guerin (bcg) organisms directly alter the growth of bladder-tumor cells. , 1994, International journal of oncology.

[96]  A. Jackson,et al.  Induction of ICAM 1 expression on bladder tumours by BCG immunotherapy. , 1994, Journal of clinical pathology.

[97]  W. Catalona,et al.  T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. , 1993, The Journal of urology.

[98]  T. Ratliff,et al.  Characterization of the internalization of bacillus Calmette-Guerin by human bladder tumor cells. , 1993, The Journal of clinical investigation.

[99]  P. McCue,et al.  Murine bladder carcinoma cells present antigen to BCG-specific CD4+ T-cells. , 1992, Cancer research.

[100]  J. Smyth,et al.  Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. , 1992, The Journal of urology.

[101]  P. Betta,et al.  Immunophenotypic characterization of the bladder mucosa infiltrating lymphocytes after intravesical BCG treatment for superficial bladder carcinoma. , 1992, European urology.

[102]  T. Ratliff,et al.  Modulation of fibronectin-mediated Bacillus Calmette-Guérin attachment to murine bladder mucosa by drugs influencing the coagulation pathways. , 1991, Cancer research.

[103]  M. Becich,et al.  Internalization of bacille Calmette-Guerin by bladder tumor cells. , 1991, The Journal of urology.

[104]  D. Coplen,et al.  Characterization of fibronectin attachment by a human transitional cell carcinoma line, T24. , 1991, The Journal of urology.

[105]  W. Coley.  The Classic: The Treatment of Malignant Tumors by Repeated Inoculations of Erysipelas , 1991 .

[106]  J. Gerdes,et al.  Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. , 1990, The Journal of urology.

[107]  L. Kavoussi,et al.  Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response. , 1990, The Journal of clinical investigation.

[108]  J. Smyth,et al.  HLA-DR expression by high grade superficial bladder cancer treated with BCG. , 1989, British journal of urology.

[109]  G. Smith,et al.  Local immune responses after intravesical BCG treatment for carcinoma in situ. , 1987, British journal of urology.

[110]  T. Ratliff,et al.  Intravesical Bacillus Calmette-Guérin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guérin. , 1987, Cancer research.

[111]  W. Catalona,et al.  Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. , 1987, The Journal of urology.

[112]  W. Catalona,et al.  Inhibition of murine bladder tumor growth by bacille Calmette-Guerin: lack of a role of natural killer cells. , 1986, Clinical immunology and immunopathology.

[113]  W. Catalona,et al.  Histological parameters and pitfalls in the interpretation of bladder biopsies in bacillus Calmette-Guerin treatment of superficial bladder cancer. , 1986, The Journal of urology.

[114]  M. Becich,et al.  Prognostic value of purified protein derivative skin test and granuloma formation in patients treated with intravesical bacillus Calmette-Guerin. , 1986, The Journal of urology.

[115]  W. Catalona,et al.  Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results. , 1985, The Journal of urology.

[116]  W. Catalona,et al.  Reduction of bladder tumor growth in mice treated with intravesical Bacillus Calmette-Guérin and its correlation with Bacillus Calmette-Guérin viability and natural killer cell activity. , 1983, Cancer research.

[117]  R L Kassel,et al.  An endotoxin-induced serum factor that causes necrosis of tumors. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[118]  B. Zbar,et al.  Immunotherapy of guinea pig cancer with bcg , 1974, Cancer.

[119]  M. Silverstein,et al.  BCG lmmunotherapy of Malignant Melanoma: Summary of a Seven-year Experience , 1974, Annals of surgery.

[120]  I. Bernstein,et al.  Immunotherapy of cancer: regression of intradermal tumors and prevention of growth of lymph node metastases after intralesional injection of living Mycobacterium bovis. , 1972, Journal of the National Cancer Institute.

[121]  B. Zbar,et al.  Immunotherapy of Cancer: Regression of Tumors after Intralesional Injection of Living Mycobacterium bovis , 1971, Science.

[122]  D. Morton,et al.  Immunological factors which influence response to immunotherapy in malignant melanoma. , 1970, Surgery.

[123]  G. Mathé,et al.  Active immunotherapy for acute lymphoblastic leukaemia. , 1969, Lancet.

[124]  B. Benacerraf,et al.  Effect of Bacillus Calmette-Guérin Infection on Transplanted Tumours in the Mouse , 1959, Nature.

[125]  R. Pearl.  On the Pathological Relations Between Cancer and Tuberculosis. , 1928 .

[126]  W. Coley.  The Treatment of Inoperable Sarcoma by Bacterial Toxins (the Mixed Toxins of the Streptococcus erysipelas and the Bacillus prodigiosus). , 1910, Proceedings of the Royal Society of Medicine.

[127]  William B. Colev.  I. The Treatment of Malignant Tumors by Repeated Inoculations of Erysipelas , 1893 .